Characterization of the immune cell landscape of patients with NAFLD
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Multiple factors are involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), but the exact immunological mechanisms that cause inflammation and fibrosis of the liver remain enigmatic. In this current study, cellular samples of a cohort of NAFLD patients (peripheral blood mononuclear cells (PBMC): n = 27, liver samples: n = 15) and healthy individuals (PBMC: n = 26, liver samples: n = 3) were analyzed using 16-color flow cytometry, and the frequency and phenotype of 23 immune cell subtypes was assessed. PBMC of NAFLD patients showed decreased frequencies of total CD3+, CD8+ T cells, CD56dim NK cells and MAIT cells, but elevated frequencies of CD4+ T cells and Th2 cells compared to healthy controls. Intrahepatic lymphocytes (IHL) of NAFLD patients showed decreased frequencies of total T cells, total CD8+ T cells, Vd2+γδ T cells, and CD56bright NK cells, but elevated frequencies of Vδ2-γδ T cells and CD56dim NK cells compared to healthy controls. The activating receptor NKG2D was significantly less frequently expressed among iNKT cells, total NK cells and CD56dim NK cells of PBMC of NAFLD patients compared to healthy controls. More strikingly, hepatic fibrosis as measured by fibroscan elastography negatively correlated with the intrahepatic frequency of total NK cells (r2 = 0,3737, p = 0,02). Hepatic steatosis as measured by controlled attenuation parameter (CAP) value negatively correlated with the frequency of circulating NKG2D+ iNKT cells (r2 = 0,3365, p = 0,0047). Our data provide an overview of the circulating and intrahepatic immune cell composition of NAFLD patients, and point towards a potential role of NK cells and iNKT cells for the regulation of hepatic fibrosis and steatosis in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275 · cited 2×
“The following clinical and demographic data were extracted by clinical chart review: age, sex, AST (asparate aminotransferase) levels, ALT (alanine aminotransferase) levels, GGT (gamma-glutamyl transferase) levels, liver elastography parameters such as liver elasticity and CAP (Controlled attenuation parameter) [13],…”
BackgroundMethodWolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Radaeva, S., Sun, R., Jaruga, B., Nguyen, V. T., Tian, Z., & Gao, B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.055 · Cited by 610
Chu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354 · cited 1×
“from all the above-mentioned tissues in parallel with analysis of soluble inflammation markers and microbial metabolites [42].”
BackgroundRau, M., Schilling, A.-K., Meertens, J., Hering, I., Weiss, J., Jurowich, C., Kudlich, T., Hermanns, H. M., Bantel, H., Beyersdorf, N., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501175 · Cited by 302 · cited 2×
“However, that pattern was not observed in the peripheral blood of NASH patients compared to NAFL patients [37].”
ResultNKT-Associated Hedgehog and Osteopontin Drive Fibrogenesis in Non-Alcoholic Fatty Liver Disease
Syn, W.-K., Agboola, K. M., Swiderska, M., Michelotti, G. A., Liaskou, E., Pang, H., Xie, G., Philips, G., Chan, I. S., Karaca, G. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301857 · Cited by 266
Bertola, A., Bonnafous, S., Anty, R., Patouraux, S., Saint-Paul, M.-C., Iannelli, A., Gugenheim, J., Barr, J., Mato, J. M., Le Marchand-Brustel, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013577 · Cited by 240 · cited 1×
“On the contrary, Bertola et al detected a shift towards the opposite direction in liver samples of NASH patients compared to S3 obese patients and obese S0 patients assessed by an increase in IL-10/IFNγ ratio [40].”
ResultThe Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity
Van Herck, M. A., Weyler, J., Kwanten, W. J., Dirinck, E. L., De Winter, B. Y., Francque, S. M., & Vonghia, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00082 · Cited by 238
NKp46-Mediated Killing of Human and Mouse Hepatic Stellate Cells Attenuates Liver Fibrosis
Gur, C., Doron, S., Kfir-Erenfeld, S., Horwitz, E., Abu-tair, L., Safadi, R., & Mandelboim, O. (2012) · Gut · doi:10.1136/gutjnl-2011-301400 · Cited by 173 · cited 1×
“It has been shown that NK cells are able to kill hepatic stellate cells (HSC) and thus protect against hepatic fibrosis in murine and human models [20].”
BackgroundHepatic natural killer T‐cell and CD8+ T‐cell signatures in mice with nonalcoholic steatohepatitis
Bhattacharjee, J., Kirby, M., Softic, S., Miles, L., Salazar‐Gonzalez, R., Shivakumar, P., & Kohli, R. (2017) · Hepatology Communications · doi:10.1002/hep4.1041 · Cited by 146
Retained NK cell phenotype and functionality in non-alcoholic fatty liver disease
Stiglund, N., Strand, K., Cornillet, M., Stål, P., Thorell, A., Zimmer, C. L., Näslund, E., Karlgren, S., Nilsson, H., Mellgren, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01255 · Cited by 72 · cited 3×
“found higher MFI of NKG2D on circulating NK cells of NASH patients compared with NAFL patients, but no correlation with hepatic fibrosis was found [11].”
BackgroundResult
Cited by
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Revisiting the Role of Natural Killer Cells in Non-Alcoholic Fatty Liver Disease
Martínez-Chantar, M. L., Delgado, T. C., & Beraza, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640869 · Cited by 67
“Singlecell-based transcriptomics studies showed that immune cellular heterogeneity and dysregulation are concomitant with the pathogenesis of NAFLD/NASH in patients (9) and in dietinduced obesity (DIO)-NASH mice (10, 11).”
BackgroundJohnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01129-y · Cited by 43
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Metadata
- Authors
- Diedrich, T., Kummer, S., Galante, A., Drolz, A., Schlicker, V., Lohse, A. W., Kluwe, J., Eberhard, J. M., & Schulze zur Wiesch, J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-03-13
- Volume
- 15
- Issue
- 3
- Pages
- e0230307
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W3011373710
- Cited by
- 78
- References
- 16
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.